RxDoctor Payments Data

Ashley Jensen

Physician Assistant · Magna, UTNPI 1396357307

Payments from drug & device makers

$1,239in general payments, 2019–2025

Across 59 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$228
  • Merck$150
  • Boston Scientific$128
  • Abbott$108
  • Inspire Medical Systems, Inc.$106
  • Indivior Inc.$94
  • plus $425 from 13 others

What the payments were for

  • Food & beverage$1,239100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,239 in reported general payments places this provider in the 75th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$2,833
Medicare patients
16
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide16$26,428
JardianceEmpagliflozin12$19,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$16,336
EliquisApixaban19$11,427
FarxigaDapagliflozin Propanediol12$10,299
MyrbetriqMirabegron13$6,453
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl22$4,420
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,570
Duloxetine Hcl27$880
Gabapentin58$813
Albuterol Sulfate HfaAlbuterol Sulfate26$641
Atorvastatin Calcium60$535
Losartan Potassium47$520
Levothyroxine Sodium50$493
Omeprazole30$486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$65$26,42816 claims
Boehringer IngelheimJardiance$68$19,07412 claims
GSKTrelegy Ellipta$15$16,33614 claims
PfizerEliquis$15$11,42719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Magna

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →